$0.6350
-0.01-2.25%
At close: -
$0.6483
0.012.09%
After Hours: Dec 20, 4:32 PM EDT
Comments
Loading...
Karyopharm Therapeutics (KPTI) Forecast
NewsEarningsKaryopharm Therapeutics (KPTI) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestKaryopharm Therapeutics (NASDAQ:KPTI) Stock Quotes, Forecast and News Summary
Karyopharm Therapeutics Stock (NASDAQ: KPTI) stock price, news, charts, stock research, profile.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy Karyopharm Therapeutics (KPTI) stock?
You can purchase shares of Karyopharm Therapeutics (NASDAQ:KPTI) through any online brokerage.
Who are Karyopharm Therapeutics (KPTI) competitors?
Other companies in Karyopharm Therapeutics’s space includes: Skye Bioscience (NASDAQ:SKYE), Anixa Biosciences (NASDAQ:ANIX), CytomX Therapeutics (NASDAQ:CTMX), bluebird bio (NASDAQ:BLUE) and Citius Oncology (NASDAQ:CTOR).
What is the forecast, or price target, for Karyopharm Therapeutics (KPTI) stock?
Karyopharm Therapeutics has a consensus price target of $6.30.
What is the current price for Karyopharm Therapeutics (KPTI)?
The stock price for Karyopharm Therapeutics (NASDAQ: KPTI) is $0.6483 last updated December 20, 2024 at 4:32 PM EST.
Does Karyopharm Therapeutics (KPTI) pay a dividend?
There are no upcoming dividends for Karyopharm Therapeutics.
When is Karyopharm Therapeutics (NASDAQ:KPTI) reporting earnings?
Karyopharm Therapeutics’s Q4 earnings are confirmed for Thursday, February 27, 2025.
Is Karyopharm Therapeutics (KPTI) going to split?
There is no upcoming split for Karyopharm Therapeutics.
What sector and industry does Karyopharm Therapeutics (KPTI) operate in?
Karyopharm Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.